Italian guidelines for antiretroviral therapy in children with human immunodeficiency virus-type 1 infection

Acta Paediatrica, International Journal of Paediatrics

Volumn 88, Issue 2, 1999, Pages 228-232

  De Martino, M ^a   Tovo, P A ^b   Giaquinto, C ^b   De Rossi, A ^b   Galli, L ^b   Gabiano, C ^b   Floridia, M ^b   Ferraris, G ^b   Ruga, E ^b   Castelli Gattinara, G ^b   Scolfaro, C ^b   Vierucci, A ^b   Vigano A ^b   Zuccotti, G V ^b   Fundaro C ^b   Caselli, D ^b   De Maria, A ^b   Duse, M ^b   Plebani, A ^b   Timpano, C ^b   Lanari, M ^b   Stegagno, M ^b   Lipreri, R ^b   Gotta, C ^b   Ruggeri, M ^b   Loriano, D ^b   Osimani, P ^b   Cellini, M ^b   Forni, G L ^b   Benaglia, G ^b   Antonellini, A ^b   De Mattia, D ^b   Pintor, C ^b   Mazza, A ^b   Romano, A ^b   Consolini, R ^b   Pignata, C ^b   Marazzi, M G ^b   Guarino, A ^b   Cecchi, M T ^b   Zizzadoro, P ^b   Battisti, L ^b   Bezzi, T ^b   Salvatore, C ^b   Ciccia, M ^b   Bionda, S ^b   Metri, A M ^b   Anastasio, E ^b   Magnani, C ^b   Sticca, M ^b   Tarallo, L ^b   Masi, M ^b   Gambaretto, G ^b   Catania, S ^b   Micheletti, E ^b   Pellegatta, A ^b   Dessi, C ^b   Baldi, F ^b   Ibba, P ^b   Bresciani, E ^b   Nasi, C ^b   Falconieri, P ^b   Tasso, L ^b   Altobelli, R ^b   Chiriaco P G ^b   Ruggeri, C ^b   Magni, L A ^b   Tondo, U ^b   Contardi, I ^b   Tommasi, D ^b   Di Gregorio, F ^b   Meo, A ^b   Resta, F ^b   Molesini, M ^b   Sabatino, G ^b   Portelli, V ^b   more..

^a UNIVERSITY OF FLORENCE   (Italy)

^b NONE

Author keywords

Antiretroviral therapy; Guidelines; HIV 1; Perinatal infection

Indexed keywords

ABACAVIR; AMPRENAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; RITONAVIR; STAVUDINE; UNCLASSIFIED DRUG; VX 141; ZALCITABINE; ZIDOVUDINE;

ADOLESCENT; ANTIVIRAL ACTIVITY; ARTICLE; CHILD; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; INFANT; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; TREATMENT FAILURE; TREATMENT INDICATION;

ANTI-HIV AGENTS; CHILD, PRESCHOOL; HIV INFECTIONS; HIV-1; HUMANS; INFANT; INFANT, NEWBORN; PATIENT COMPLIANCE; TREATMENT FAILURE;

EID: 0033047797     PISSN: 08035253     EISSN: None     Source Type: Journal    
DOI: 10.1080/08035259950170457     Document Type: Article

References (26)

1. 1. Tovo P-A, de Martino M, Caramia G, Armenio L, Schettini F, De Mattia D, et al. Epidemiology, clinical features, and prognostic factors of paediatric HIV infection. Lancet 1988; ii: 1042-5
2. 2. de Martino M, Tovo P-A, Galli L, Gabiano C, Cozzani S, Gotta C, et al. Prognostic significance of immunologic changes in 675 infants perinatally exposed to human immunodeficiency virus. J Pediatr 1991; 119: 702-9
3. 3. de Martino M, Tovo P-A, Galli L, Caselli D, Gabiano C, Mazzoni PL, et al. HIV-1 infection in perinatally exposed siblings and twins. Arch Dis Child 1991; 66: 1235-8
4. 4. de Martino M, Tovo P-A, Tozzi AE, Pezzotti P, Galli L, Livadiotti S, et al. HIV-1 transmission through breast-milk: appraisal of risk according to duration of feeding. AIDS 1992; 6: 991-7
5. 5. Gabiano C, Tovo P-A, de Martino M, Galli L, Giaquinto C, Loy A, et al. Mother-to-child transmission of human immunodeficiency virus type 1: risk of infection and correlates of transmission. Pediatrics 1992; 90: 369-74
6. 6. Tovo P-A, de Martino M, Gabiano C, Cappello N, D'Elia R, Loy A, et al. Prognostic factors and survival in children with perinatal HIV-1 infection. Lancet 1992; 339: 1249-53
7. 7. Galli L, de Martino M, Tovo PA, Gabiano C, Zappa M, Giaquinto C, et al. Onset of clinical signs in children with HIV-1 perinatal infection. AIDS 1995; 9: 455-61
8. 8. de Martino M, Tovo P-A, Galli L, Gabiano C, Veglia F, Giaquinto C, et al. Features of children perinatally infected with HIV-1 surviving longer than 5 years. Lancet 1994; 343: 191-5
9. 9. Tovo P-A, de Martino M, Gabiano C, Cappello N, Giaquinto C, Tulisso S, et al. Mode of delivery and gestational age influence perinatal HIV-1 transmission. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 11: 88-94
10. 10. Tovo PA, de Martino M, Gabiano C, Galli L, Ferraris G, Marchisio P, et al. Long-term nonprogressors among children with perinatal HIV-1 infection. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 15 Suppl 1: S19-22
11. 11. Registro Italiano per l'Infezione da HIV in Pediatria. Linee guida sulla terapia antiretrovirale in bambini con infezione da HIV-1. Riv Ital Ped. In press
12. 12. European Collaborative Study. Age-related standards for T lymphocyte subsets based on uninfected children born to human immunodeficiency virus 1-infected women. Ped Infect Dis J 1992; 11: 1018-26
13. 13. Gibb DM, Newberry A, de Rossi A, Kaye S, Loveday C, Munoz-Fernandez A, et al. HIV-1 viral load and CD4 count in untreated children with vertically acquired asymptomatic or mild disease. AIDS 1998; 12: F1-8
14. 14. Mellors JW, Munoz A, Giorgi JV, Margolick JB, Tassoni CJ, Gupta P, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997; 126: 946-54
15. 15. Mofenson LM, Korelitz J, Meyer WA, Bethel J, Rich K, Pawha S, et al. The relationship between serum human immunodeficiency virus type 1 (HIV-1) RNA level, CD4 lymphocyte percent, and long-term mortality risk in HIV-1-infected children. J Infect Dis 1997; 175: 1029-38
16. 16. Shearer WT, Quinn TC, LaRussa P, Lew JP, Mofenson L, Almy S, et al. Viral load and disease progression in infants infected with human immunodeficiency virus type 1. N Engl J Med 1997; 336: 1337-42
17. 17. Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O'Sullivan MJ, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994; 331: 1173-80
18. 18. Centers for Disease Control and Prevention. Public Health Service Task Force recommendations for the use of antiretroviral drugs in pregnant women with HIV-1 for maternal health and for reducing perinatal HIV-1 transmission in the United States. Morb Mortal Wkly Rep 1998; 47 (RR-2): 1-30
19. 19. Mayers DL. Prevalence and incidence of resistance to zidovudine and other antiretroviral drugs. Am J Med 1997; 102: 70-5
20. 20. Centers for Disease Control. 1994 revised classification system for human immunodeficiency virus infection in children less than 13 years of age. Morb Mortal Wkly Rep 1994; 43 (RR-12): 1-10
21. 21. Working Group on Antiretroviral Therapy and Medical Management of HIV Infected Children. Guidelines for the use of antiretroviral agents in pediatric HIV infection. Morb Mortal Wkly Rep 1998; 47 (RR-4): 1-43
22. 22. Luzuriaga K, Bryson Y, Krogstad P, Robinson J, Stechnberg B, Lamson M, et al. Combination treatment with zidovudine, didanosine, and nevirapine in infants with human immunodeficiency virus type 1 infection. N Engl J Med 1997; 336: 1343-9
23. 23. Monpoux F, Sirvent N, Cottalorda J, Mariani R, Lefbvre JC. Stavudine, lamivudine and indinavir in children with advanced HIV-1 infection: preliminary experience. AIDS 1997; 11: 1523-5
24. 24. Rutstein RM, Feingold A, Meilich D, Word B, Rudy B. Protease inhibitor therapy in children with perinatally acquired HIV infection. AIDS 1997; 11: F107-11
25. 25. Japour A. Future aspects in protease inhibitor therapy. Sixth European Conference on Clinical Aspects and Treatment of HIV infection, Hamburg, 1997;
26. 26. Raffi F, Pialux G, Brun Vezinet F, Gastaut JA, Dellamonica P, Delfraissy JF, et al. Results of trilege trial, a comparison of three mantenance for HIV infected adults receiving induction therapy with ZDV, 3TC and Indinavir. 5th Conference on retrovirus and opportunistic infections, Chicago, 1998